GLP-1 receptor agonists like semaglutide produce characteristic facial changes during rapid weight loss, involving deflation of superficial fat compartments, loss of deep structural support, skeletal resorption, and increased skin laxity. Midfacial volume loss occurs predominantly in superficial fat layers, creating contour flattening and pronounced transition lines that accelerate visible aging. This anatomical understanding represents a significant advancement in cosmetic medicine's approach to weight-loss patients. The findings challenge the assumption that facial changes from rapid weight loss are uniform, revealing instead a predictable pattern of compartment-specific volume depletion. For the millions using GLP-1 medications, this research provides crucial insight into managing an unexpected consequence of successful weight management. The recommended multimodal treatment combining early collagen stimulation with targeted hyaluronic acid fillers addresses both tissue quality and structural support. While this represents incremental progress in aesthetic medicine, the clinical relevance is substantial given the explosive growth in GLP-1 usage. The anatomically-informed approach could help patients maintain facial aesthetics while achieving metabolic benefits, though long-term outcomes and optimal intervention timing remain undefined.